NCT05420493 is a Phase 1 clinical trial of CAR-T cells in Relapsed Non-Hodgkin Lymphoma, sponsored by Chongqing Precision Biotech Co., Ltd.

Who is sponsoring NCT05420493?

NCT05420493 is sponsored by Chongqing Precision Biotech Co., Ltd.

What drugs are being tested in NCT05420493?

Interventions in NCT05420493: CAR-T cells.

What condition does NCT05420493 study?

NCT05420493 studies Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma.

Is NCT05420493 still recruiting?

NCT05420493 is currently status unknown. Last updated 5 January 2024.

Last reviewed 2024-01-05 · How we verify

NCT05420493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Status unknown Phase 1 Last updated 5 January 2024

What this trial tests

Phase 1 trial testing CAR-T cells in Relapsed Non-Hodgkin Lymphoma in 54 participants. Status unknown.

Timeline

6 September 2021

Primary endpoint
30 September 2024

30 September 2025

Quick facts

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	6 September 2021
Primary completion	30 September 2024
Estimated completion	30 September 2025
Sites	1 location across China

Drugs / interventions tested

CAR-T cells

Conditions studied

Relapsed Non-Hodgkin Lymphoma — all drugs for Relapsed Non-Hodgkin Lymphoma →
Refractory Non-Hodgkin Lymphoma — all drugs for Refractory Non-Hodgkin Lymphoma →
Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →

Sponsor

Chongqing Precision Biotech Co., Ltd — full company profile →

Who can join

18 and older, any sex, with Relapsed Non-Hodgkin Lymphoma or Refractory Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and strategies associated with CAR-T cell therapy in blood malignancies.
Liu Z, Lei W, Wang H, Liu X, et al · · 2024 · cited 23× · PMID 38402232 · DOI 10.1186/s40164-024-00490-x
Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.
Feng Y, He C, Liu C, Shao B, et al · · 2024 · cited 4× · PMID 38928150 · DOI 10.3390/ijms25126444

Verify or expand the search:

Other trials of CAR-T cells

Trials testing the same drug.

NCT06481228 — Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL · NA · recruiting
NCT06429150 — Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma · Phase 1, PHASE2 · recruiting
NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
NCT05779917 — Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers · Phase 1 · recruiting
NCT06698484 — To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non · Phase 2 · recruiting

Other recruiting trials for Relapsed Non-Hodgkin Lymphoma

Currently open trials in the same condition.

NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06158386 — Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma · Phase 2 · recruiting
NCT06026319 — CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · Phase 1 · recruiting
NCT06119685 — IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers · Phase 1, PHASE2 · recruiting

Other Chongqing Precision Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05420493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
Last refreshed: 5 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05420493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing